Gut microbiota associated with cancer immunotherapy outcomes

Wafik S. El-Deiry shared on X:

“Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome.

‘Gut dysbiosis TOPOSCORE computed from lung cancers could be applied to other cancers.’

‘The metagenomics-based score was translated into a rapid 21-bacteria-based qPCR test.’”

Additional information.
Source: Wafik S. El-Deiry/X

Wafik El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals.

Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.